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In order to present an antigen to T-cells, the antigen must
first be degraded by proteasomes. Following exposure to
interferons, some proteasome subunits (ß1,ß2,ß5) are replaced
by others (LMP2, LMP7, MECL-1) that have more optimal
catalytic properties for peptide presentation; this more efficient
organelle is termed the immuno-proteasome. Here we
measured gene expression of various subunits in peripheral
mononuclear cells of patients with IgA nephropathy, a disease
with features of immune dysregulation. We used quantitative
PCR to measure the expression of proteasomal subunit mRNA
in mononuclear cells from IgA nephropathy patients, a group
of proteinuric control patients with idiopathic nephrotic
syndromes, and healthy controls. A significant switch in the
expression of trypsin- and chymotrypsin-like proteasome
subunits to corresponding immuno-proteasome subunits was
found in patients as compared to healthy controls. Further, we
found that nuclear translocation of NF-jB p50 and p65 was
significantly greater in the IgA nephropathy patients, but this
did not correlate with the switch to the immuno-proteasome
phenotype. Patients with proteinuria greater than 0.5 g/
1.73 m2/day had a significant switch of the chymotryptic-like b5
protease to the LMP7 subunit, but this did not occur in patients
with idiopathic nephrotic syndrome. The switch to an immuno-
proteasome in peripheral blood mononuclear cells of patients
with IgA nephropathy suggests an increased efficiency of
antigen processing and presentation. This switch appears to be
independent of a coincidental activation of the NF-jB pathway
but is associated with high levels of proteinuria, a well known
risk factor for progression of IgA nephropathy.
Kidney International (2009) 75, 536–541; doi:10.1038/ki.2008.579;
published online 26 November 2008
KEYWORDS: IgA nephropathy; proteasome; immunoproteasome;
transcription factors; NF-kB; proteinuria
Class A immunoglobulin (IgA) nephropathy (IgAN) is a
chronic glomerular disease characterized by mesangial
deposits of IgA likely due to an accumulation of IgA immune
complexes.1 IgAN is characterized by a dysregulation of the
immune system, with an altered response to environmental
antigens eventually leading to synthesis and mesangial
deposition of aberrantly glycosylated polymeric IgA1.2
Although the origin of deglycosylated IgA1 remains un-
known, a function for a particular cytokine milieu has been
suggested from experimental models.3
Among the recently identified new actors in the regulation
of the immune response, the proteasome (PS) has been the
focus of great interest, as it controls many crucial cell
functions,4 including the cell-cycle progression, the activation
of transcriptional factors, such as nuclear factor-kB (NF-kB),
and the production of cytokines and chemokines. Antigen
processing and presentation onto major histocompatibility
complex (MHC) class I molecules also are under proteasomal
control.5
The PS is a 26S complex containing a 20S multicatalytic
core and two 19S regulatory complexes. The 20S core is
composed of 4 seven-member rings. The two outer rings are
formed by a subunits, whereas the two inner rings contain b
subunits; the b1, b2, and b5 subunits have caspase-like,
trypsin-like, and chymotrypsin-like activities for cleavage of
acidic, basic, and hydrophobic amino acids, respectively.6 The
interferons (IFN-g or -a) induce a switch to a new PS form,
the so called immunoproteasome (iPS), by replacing the b1
subunit with the low-molecular-weight protein 2 (LMP2),
the b2 subunit with the endopeptidase complex-like-1
(MECL-1), and the b5 subunit with the LMP7.7 The switch
to iPS improves the catalytic proteasomal activities and leads
to optimal MHC-I peptide presentation and T-cell response.8
The aim of this study was to investigate the PS and iPS
system in patients with IgAN. We therefore evaluated mRNA
encoding for the active subunits of PS and iPS in peripheral
blood mononuclear cells (PBMCs) from patients with IgAN,
taking into consideration also their clinical features, renal
biopsy grading, and type of therapy.
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RESULTS
We considered 55 patients in whom a diagnosis of IgAN was
performed by renal biopsy eligible for the study (relevant
data in Table 1). Histologic grading showed prevalence of
moderate lesions (60%). All patients had a creatinine
clearance 490 ml/min/1.73 m2. A total of 22 patients had
proteinuria 40.5 g/1.73 m2/day. In the previous 3 months, 23
patients were treated with angiotensin inhibitors (either ACE
inhibitors or angiotensin II receptors blockers), 7 with
prednisone, whereas the other 26 had no treatment. None
was assuming statins or other anti-inflammatory drugs. A
disease control group of 30 patients with idiopathic
nephrotic syndrome, as well as 50 age and sex-matched
healthy controls (HCs) was also investigated (Table 1).
We detected a significant switch of the trypsin-like
(MECL-1/b2) and chymotrypsin-like (LMP7/b5) catalytic
PS subunits mRNA to the iPS corresponding subunits in
patients with IgAN (MECL-1/b2: 1.49±0.89 (s.d.) versus
1.02±0.30 in HC, P¼ 0.0044; LMP7/b5: 1.73±1.36 versus
1.07±0.33 in HC, P¼ 0.0083) (Figure 1; Table 2). There was
a highly significant correlation (Po0.0001) of these two iPS/
PS ratios in IgAN patients (Figure 2). The disease control
group of children and adolescents with idiopathic nephrotic
syndrome showed a switch limited to one of the three iPS
(MECL-1/b2: 1.93±2.25, P¼ 0.0249 versus HC). The other
iPS subunits were similar to HC (LMP2/b1: 1.17±0.66,
P¼ 0.0755 versus HC; LMP7/b5: 1.12±0.45, P¼ 0.6678
versus HC). No correlation was found among PS/iPS mRNA
ratios in this diseased group and healthy controls.
The mean values of the switch of the caspase-like catalytic
subunits (LMP2/b1) were similar in patients and nephrotic
syndrome or healthy controls and not correlated with
the trypsin-like and chymotrypsin-like catalytic subunits
(Figure 1; Table 2).
In a control group of subjects with respiratory or
gastrointestinal infections without urinary involvement, the
switch was completely different from what observed in
patients with IgAN, as MECL-1/b2 mRNA ratio, which was
increased in IgAN, was found to be decreased (0.69±0.36,
Po0.02 versus IgAN), whereas LMP2/b1, which was not
affected in IgAN, was significantly increased (2.4±1.1 in
infectious controls, Po0.001 versus both IgAN and healthy
controls).
Patients with IgAN also had a significantly increased
expression of the structural PS and iPS a2 subunit mRNA in
comparison to HC (Po0.05) (Figure 3). Neither linear nor
nonlinear correlation was found between a2 mRNA levels in
patients or in controls and the PS or iPS mRNA expression
for either the catalytic subunit or the iPS/PS mRNA ratios.
Nuclear translocation of p50 and p65 active subunits of
NF-kB was found to be significantly greater in PBMCs
of patients with IgAN than in healthy controls (p50:
275.8±341.7 versus 69.9±59.8, P¼ 0.0413; p65:
287.3±95.2 versus 110.9±130.4, P¼ 0.0001) (Figure 4;
Table 2). No significant correlation was found between
NF-kB nuclear binding in PBMCs of patients with IgAN and
the switch from PS to iPS mRNAs.
We sought correlations between the switch from PS to iPS
mRNA and clinical data of the IgAN patients investigated. No
correlation was found with age, sex, disease duration, or
creatinine clearance. No correlation between histologic
grading of the renal biopsy and PS/iPS switch was detected.
The switch of the chymotrypsin-like catalytic subunits
(LMP7/b5) mRNA in IgAN with proteinuria 40.5 g/1.73 m2/
day was significantly higher than in patients with lower levels
(2.25±1.89 versus 1.34±0.72, P¼ 0.0182) (Figure 5). No
correlation with the therapy assumed, either angiotensin
inhibitors or corticosteroids, was observed.
No correlation with proteinuria was found in the disease
control group of idiopathic nephrotic syndromes.
DISCUSSION
In patients with IgAN, several lymphomonocyte abnormal-
ities have been reported, such as increased CD4 subset,9 and a
peculiar gene expression profile in cases with progressive
renal disease.10 This report highlights that PBMCs of patients
with IgAN have a significant switch from PS to iPS mRNAs.
The difference with healthy controls is mostly evident in the
changes concerning the trypsin-like and chymotrypsin-like
catalytic PS subunits, which were significantly correlated. The
whole PS and iPS mass is likely to be increased too, as
indicated by the increase in the mRNA encoding for the a2
subunits, which are structural components of both the PS
and the iPS. A disease control group of children and
adolescents with idiopathic nephrotic syndrome with various
levels of proteinuria showed a switch limited to one of the
three iPS (MECL-1/b2), without correlation with the other
iPS and without correlation with the extent of proteinuria.
The switch from PS to iPS is thought to be aimed at
improving the proteasomal catalytic properties for optimal
MHC-I peptide presentation.5 Indeed, the iPS provides a
particular professional antigen processing, leading to im-
proved peptide presentation to reactive T cells. This goal is
reached by preparing the C terminus of the peptide residues
to the high affinity bond with the MHC class I cleft. iPS is
upregulated in dendritic cells when they migrate to the lymph
Table 1 | Relevant clinical data of the 56 patients with IgAN
and HCs investigated
HC IgAN
Gender: males/females 41/9 45/10
Age (years) 21.22±6.18
(2.3–40.5)
20.5±8.3 (4.3–39.5)
Time (years) from renal biopsy — 4.4± 4.4 (0–18.4)
Proteinuria (g/day) — 0.89±0.86 (0–3.85)
Creatinine clearance (ml/min/
1.72 m2)
121.53±10
(93–140)
122±12 (92–140)
Histological classification —
Grade I mild 19/55 (35%)
Grade II moderate 33/55 (60%)
Grade II severe 4/55 (5%)
IgAN, IgA nephropathy; HC, healthy control.
Data are expressed as means±standard deviations and ranges in brackets.
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nodes to stimulate T cells.11 Circulating monocytes are likely
to be mostly involved in the switch to iPS found in our IgAN
patients, as it was detected in some experiments on purified
adherent blood cells (data not shown).
The novelty of our finding leaves the mechanism/s
responsible for the upregulation of the iPS in IgAN to be
elucidated. A switch from PS to iPS has been reported in
some systemic autoimmune disorders,12 and in IFN-induced
antiviral states.13,14 Indeed, IFNs are considered major actors
in the switch from PS to iPS in immunocompetent cells.15 We
recently reported a significantly higher expression of iPS
genes (LMP7/b5) in children with hepatitis C viral (HCV)
infection, which was supposed to lead to an increased
presentation of self-antigens onto MCH-I molecules, ulti-
mately resulting in enhanced autoimmune responses.16 A
function for infectious agents in triggering IgAN, as
suggested by the typical gross hematuria in coincidence with
upper respiratory tract infections, has been researched for
decades.1 Our finding of a switch from PS to iPS, measured
as a ratio between iPS/PS catalytic subunits mRNAs, in
PBMCs of patients with IgAN may reflect a response to
infectious challenges, for example viral infections, with an
increased release of IFNs. This scenario fits with a Th1
lymphocyte prevalence and Th1 cytokine release in IgAN.
This hypothesis is supported by recent observations which
suggest a possible function for Th1 prevalence in experi-
mental animal models.17 A Th1/Th2 balance polarization
toward Th1 has been reported in the ddY strain of mice with
spontaneous IgAN, and it was particularly evident at the
beginning of the disease.17 The production of IFN-g has also
been suggested as influencing the risk of renal failure in mice
with IgAN induced by Sendai virus.18,19 Th2 cytokines have
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Figure 1 | Individual results of the switch from proteasome (PS) to immunoproteasome (iPS) detected as a ratio between each iPS
catalytic unit (LMP2, LMP7, MECL-1) and the corresponding PS (b1, b2, b5) mRNA in patients with IgA nephropathy (IgAN) and
healthy controls (HC).
Table 2 | Densitometric data (arbitrary units) of mean levels
and standard deviations of the switch from PS to iPS as a
ratio between each iPS catalytic subunit (LMP2, LMP7, MECL-
1) mRNA and the corresponding PS subunits (b1, b2, b5);
mRNA nuclear binding activity of the two active subunits of
the transcription factor NF-jB p50 and p65; significance of
the differences (P) between values in patients with IgAN and
HCs
HC IgAN P
LMP2/b1 0.91±0.42 1.01±0.65 NS
MECL-1/b2 1.02±0.30 1.49±0.89 0.0044
LMP7/b5 1.07±0.33 1.73±1.36 0.0083
NF-kB p50 69.9±59.8 275.8±341.7 0.0413
NF-kB p65 110.9±130.4 287.3±95.2 0.0001
IgAN, IgA nephropathy; HC, healthy control; NS: not significant; PS, proteasome; iPS,
immunoproteasome; LMP2, low-molecular-weight protein 2; LMP7, low-molecular-
weight protein 7; MECL-1, b2 subunit with the endopeptidase complex-like-1.
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Figure 2 | A highly significant correlation was found between
the two switches from PS to iPS mRNAs (MECL-1/b2 and
LMP7/b5) in patients with IgA nephropathy. The correlation
was not significant in patients with idiopathic nephrotic
syndrome or in healthy controls (data not shown).
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rather supposed to have a function in aberrant glycosylation
of serum IgA.20
It is of interest that the iPS switch we found in patients
with IgAN does not seem to be a simple expression of a
concomitant acute infectious disease, as in the control group
of subjects with respiratory of intestinal acute febrile disease
the iPR/PS pattern was completely different from what
observed in IgAN.
An IFN-mediated switch from PS to iPS elicited by viral
infections may result in NF-kB activation. In fact, the
ubiquitin/PS pathway is a major regulator of NF-kB
activation4 being responsible for the degradation of NF-kB
and of its inhibitory factor IkB. Hence, we investigated the
relationship between NF-kB and the PS/iPS system in
PBMCs in our patients with IgAN. We detected an increased
nuclear translocation of the p50 and p65 active subunits of
NF-kB, although this did not correlate with the switch from
PS to iPS mRNAs. Therefore, a function for other mediators
released during infections may be inferred. An increase in
iPS, besides being possibly caused by viral induction of IFNs,
has more recently been thought as being part of a response to
oxidative stress, reflecting a compensatory, albeit insufficient,
response to it, in age-related macular degeneration.21
Notably, in IgAN there is an enhanced oxidative stress,
leading to increased advanced oxidative stress protein
products in progressive cases.22
The switch from PS to iPS of the chymotrypsin-like
catalytic subunits (LMP7/b5) was significantly higher in
IgAN patients with high proteinuria levels than in those in
clinical remission. This association is of interest, as
proteinuria is the most relevant risk factor for progression
of IgAN.23 No correlation with the therapy, either angio-
tensin antagonists or corticosteroids, was observed. No
correlation with histologic grading was also observed, but
the wide range of time elapsed since renal biopsy must be
taken into account.
In conclusion, this is the first report of an upregulation of
iPS PBMC of subjects with a renal disease, namely IgAN,
suggesting an enhancement of the efficiency of the immune
response to certain MHC-I antigens. The reports on switch
from PS to iPS in human diseases are only a few (12, 14, 20)
and the knowledge of the signals involved remains mostly
speculative, like in our study. It is of note that in none of the
few studies investigating iPS in clinical settings, all the three
subunits are switched at the same time and the reasons are
unknown. We do not know why in IgAN only two of the
three iPS subunits are switched, one of them (LMP7/b5)
being more correlated with proteinuria. It is of interest that
the other iPS which failed to show a switch in patients with
IgAN (LMP2/b2) was selectively increased in the control
group of patients with febrile infectious disease without renal
involvement.
It is presently impossible to say whether the switch from
PS to iPS in PBMC of patients with IgAN reflects a response
to infectious challenge. From the data detected in subjects
with idiopathic nephrotic syndrome or with chronic viral
infection, the switch from PS to iPS results not to be unique
to IgAN, but the extent of subunits involved and the
correlations with proteinuria we found in IgAN only, are
relevant. It is of interest that genes involved in the iPS
pathway have been found to be activated in IgAN during
phases of clinical activity.24 Further studies are needed to
clarify whether the switch from PS to iPS that we detected in
patients with IgAN has any function in pathogenesis and/or
progression of the disease.
MATERIALS AND METHODS
Subjects
Patients with biopsy-proven diagnosis of IgAN, consecutively referred to
the Nephrology, Dialysis and Transplant Unit of the Regina Margherita
Children’s Hospital, Turin, and of the Policlinico San Matteo, Pavia,
from September 2004 to March 2007 were enrolled in the study. The
histologic classification of IgAN in three grades of renal lesions (grade I:
mild, grade II: moderate, grade III: severe) was performed according to a
recent report.25 Patients with Henoch-Schoenlein purpura nephritis,
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Figure 3 | PS and iPS a2 subunit mRNA values in patients with
IgA nephropathy (IgAN) and in healthy controls (HCs).
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Figure 4 | Nuclear translocation of p50 and p65 subunits of
NF-jB in patients with IgA nephropathy and in healthy
controls.
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Figure 5 | LMP7/b5 mRNA ratio of iPS/PS subunits in patients
with IgA nephropathy in remission (proteinuria p0.5 g/1.73 m2
per day) and with proteinuria 41 g/1.73 m2 per day.
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lupus, celiac disease, chronic liver disease, or diabetes mellitus as well as
those who expressed their unwillingness to blood sampling were
excluded. As disease control population, we investigated 30 children and
young subjects (mean age 8.8±7.6) with idiopathic nephrotic syndrome
(13 had renal biopsy showing focal segmental glomerulosclerosis, and 12
minimal change disease), consecutively presenting for visit or
hospitalization in the Nephrology center in Turin. They were in various
phase of renal activity, with mean 24 h proteinuria 7.12±9.3 g/1.73 m2
per day (range 0.1–15). A total of 9 were assuming steroids and 20
immunosuppressive drugs. Their CrCl was 111±99 ml/min per
1.73 m2. A group of 15 children and adolescents (mean age 6.7±8.2)
with respiratory or gastrointestinal infections without any detectable
urinary involvement was investigated as well. They presented with acute
febrile gastrointestinal diseases (stool culture negative for bacteria)
(eight cases), viral pneumonia (two cases), febrile acute pharyngitis
(four cases), and infectious mononucleosis (one case). As a healthy
control population, a group of sex- and age-matched healthy subjects
were randomly selected. All patients and controls were Italian
Caucasians.
Creatinine clearance (CrCl) was calculated from blood and 24 h
urine samples and corrected for the body surface area in both
children and adults, in an effort to homogenize units of
measurement in various ages. Similarly, 24 h proteinuria was
corrected for 1.73 m2, in order to have a common unit of
measurement in children and adults. Urine collections ±7 days
the date of serum sampling were available in 54 of 55 patients with
IgAN. Proteinuria 40.5 g/1.73 m2 per day was considered as sign of
clinical activity of IgAN, as we did in a previous trial enrolling
children and adults.26
The study was performed according to the usual guidelines and
ethical principles for medical research, and informed consent was
obtained from each participant. The study protocol conformed to
the guidelines of the ethical committee of the two hospitals which
enrolled the IgAN patients.
Peripheral blood mononuclear cells isolation
PBMC were separated by Fycoll-Hypaque density gradient (Sigma
Co., St. Louis, MO, USA) according to standard protocols. More
than 95% of cells were viable when tested by the Trypan blue
exclusion test.
Reverse transcription
Total RNA was extracted from cells using the TRI-Reagent kit
(Sigma) according to manufacturer’s protocol.
Total RNA (1 mg) was reverse transcribed with 5 ml of PCR buffer
II 10 , 11 ml of MgCl2 25 mM, 2 ml reverse-transcriptase MuLV
50 U/ml (murine Moloney leukemia virus), 1 ml of RNase inhibitor
20 U/ml, 5 ml random hexamers 50 mM (Applied Biosystems, Foster
City, CA, USA), 1 ml mix dNTPs 100 mM (Amersham, Piscataway,
NJ, USA), and dd-water in a final volume of 50 ml.
The reaction mix was carried out in a GeneAmp PCR system
9700 Thermal Cycle (Applied Biosystems) at the following
conditions: 10 min at 20 1C, 45 min at 42 1C, and 5 min at 99 1C
for the inactivation of enzyme; the cDNAs were stored at 80 1C.
Relative quantification by real-time PCR
Quantification of IP and PS mRNA expression was normalized to
the expression of Abl, chosen as a reference gene and was achieved
by means of the ABI PRISM 7700 Sequence Detection System (PE
Applied Biosystems). We used a set of primers and a fluorogenic
oligonucleotide probe designed to hybridize to the specific target
sequence (Assay-on-Demand: a2Hs00541050_m1, bHs00382586_m1,
b2Hs00160607_m1, b5Hs00655652_m1, LMP-2Hs00544762_m1,
MECL-1Hs00160620_m1, LMP-7Hs00544758_m1, Abl Hs00245445
(Applied Biosystems). To obtain the quantification of IP (LMP-2,
LMP-7, and MECL-1) and PS (b1, b2, and b5) we applied the DDCt
method. The DDCt method is a relative quantification of target
genes expression (IP and PS) in the patients compared with normal
samples. The data obtained were analyzed using the comparative
cycle threshold (Ct) method. To determine the quantity of IP and PS
expression, Ct values were first normalized by subtracting the Ct
value obtained from the Abl (reference gene, DCt¼Ct IP/PSCt
Abl). Relative IP and PS mRNA fold changes were calculated by
subtracting the normalized Ct value of our patients from the
controls (DDCt¼DCt patientsDCt controls) and the relative IP
and PS fold changes were determined 2DDCt.
Western blotting
Nuclear extracts were prepared from PBMC as described previously.
For the preparation of whole cell lysates, cells were lysed in a buffer
containing 20 mmol/l HEPES pH 7.9, 1.5 mmol/l MgCl2, 420 mmol/l
NaCl, 0.2 mmol/l EDTA, 1 mmol/l DTT, 1 mmol/l PMSF, 25%
glycerol. Protein concentration of protein lysates was determined
using BCA assay (Pierce; Perbio Science, Bonn, Germany). For the
detection of nuclear localized NF-kB family members, B20 mg of
nuclear extracts was separated on a 12% SDS–PAGE and transferred
onto PVDF transfer membrane (GE Healthcare–Amersham,
Fairfield, CT, USA). The blot was probed with antibodies against
NF-kB p65 (SC-109, rabbit polyclonal; Santa Cruz Biotechnology,
Santa Cruz, CA, USA), NF-kB p50 (SC-7178, rabbit polyclonal;
Santa Cruz Biotechnology).
Incubation of all primary antibodies was followed by incubation
with an appropriate horseradish peroxidase-conjugated secondary
antibody. Bands were visualized by enhanced chemiluminescence
staining and quantified by the Image Master Total lab 2.0 software
(Amersham).
Statistical analysis
The normal distribution of variables was tested by means of the one-
sample Kolmogorov–Smirnov test. Normally distributed variables
were analyzed by means of the independent-sample t-test (for two
groups). Nonnormally distributed variables were analyzed by means
of the Mann–Whitney test. Data were expressed as mean±standard
deviation (s.d.). Pearson’s test was used to correlate two series of
normally distributed data. Statistics software SPSS 14.0 was used to
elaborate data (SPSS Inc., Chicago, IL, USA).
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